Spectral AI to Feature DeepView® System at 2026 American Burn Association Annual Meeting
Rhea-AI Summary
Spectral AI (Nasdaq: MDAI) will exhibit its DeepView® System at the American Burn Association Annual Meeting, April 14-17, 2026 in Orlando, Booth 601.
The company will offer hands-on demonstrations, an ABA Innovation Theater overview on April 14 at 5:30 pm, and multiple podium and poster presentations. Spectral AI submitted a De Novo 510(k) application for DeepView to the FDA in June 2025.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – MDAI
On the day this news was published, MDAI declined 0.60%, reflecting a mild negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $336K from the company's valuation, bringing the market cap to $55.69M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AI/medtech peers show mixed tape, but momentum scanner flags XTNT up 3.47% and LUNG up 3.88%, with ICCM down 2.58%. Sector summary notes 2 peers moving up (median 3.7%), suggesting broader medical device momentum alongside MDAI’s 2.44% pre-news gain.
Previous AI Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | CFO appointment | Positive | +2.4% | New CFO with public company and capital markets experience joins May 4, 2026. |
| Mar 18 | BARDA funding award | Positive | +18.3% | $31.7M BARDA award to accelerate DeepView System feature development for burn imaging. |
| Feb 10 | CEO appointment | Positive | +0.7% | New CEO appointed to lead commercialization of DeepView AI-driven burn assessment device. |
| Feb 02 | Awareness week participation | Neutral | -2.9% | Participation in National Burn Awareness Week in partnership with American Burn Association. |
| Oct 23 | Equity financing | Negative | -0.9% | $7.6M equity and warrant financing to fund DeepView expansion and readiness. |
AI-tag news has usually seen modest positive alignment, with one strong upside reaction to BARDA funding and only one clear divergence on a neutral awareness event.
Over the past months, Spectral AI has focused on its DeepView® burn assessment platform and corporate build-out. AI-tag events included BARDA funding of $31.7M, CEO and CFO appointments tied to commercialization, and participation in burn-awareness initiatives, all anchored around the June 2025 De Novo FDA submission. Today’s ABA conference showcase continues this pattern of product- and awareness-focused updates supporting the DeepView launch narrative.
Historical Comparison
AI-tag news over the last five events produced an average move of 3.53%, mostly positive. Today’s ABA-focused DeepView showcase fits the pattern of product and awareness milestones rather than major financing or BARDA-type inflection points.
AI-tag history shows steady DeepView progression: BARDA funding, leadership changes toward commercialization, awareness partnerships with the American Burn Association, and now a hands-on ABA meeting presence following the June 2025 De Novo FDA submission.
Regulatory & Risk Context
An effective S-3 shelf filed on 2025-10-30 registers up to 4,989,502 shares for resale from previously issued warrants and pre-funded warrants. The company states it will not receive proceeds from selling stockholders’ resales, though it may receive cash if warrants are exercised for cash. This structure adds a resale overhang but not a new primary capital raise.
Market Pulse Summary
This announcement centers on showcasing the DeepView® System at the American Burn Association meeting, reaching more than 2,200 burn-care professionals and providing hands-on demonstrations. It builds on earlier milestones, including the June 2025 De Novo 510(k) submission and BARDA funding to advance DeepView. Investors may track FDA review progress, further clinical data, and additional adoption-focused events to gauge how this visibility translates into commercialization momentum.
Key Terms
de novo 510(k) regulatory
510(k) regulatory
multispectral imaging medical
ai algorithm technical
AI-generated analysis. Not financial advice.
DeepView System will be on Display at Booth #601
DALLAS, April 09, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its participation in the upcoming Annual Meeting of the American Burn Association, being held April 14-17, 2026 in Orlando, Florida. The Company’s DeepView® System will be on display at Booth 601.
This premier industry event for burn care education, research, and collaboration brings together more than 2,200 clinicians, researchers, and burn care leaders from across the globe.
The theme for this year’s event is “Leading Burn Care into Tomorrow.” To that end, Spectral AI will be:
- Offering a hands-on demonstration of the DeepView System, a predictive diagnostic device and associated software platform that combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of burn wounds. The DeepView System provides clinicians with an immediate, data-driven assessment of whether a burn wound will heal on its own or requires significant medical intervention, enabling earlier and more informed treatment decisions. Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the U.S. Food and Drug Administration (FDA) in June 2025.
- Presenting an overview of the DeepView System, including real world experience, at the ABA Innovation Theater on April 14, 2026 at 5:30 pm local time. The event will be hosted by Christopher J. Lewis FRCS (Plast), Consultant Plastic & Reconstructive Surgeon in Newcastle upon Tyne, working within the NHS at the Royal Victoria Infirmary.
The DeepView System will also be included in several podium and poster presentations during the event.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
| Investors: | |
| The Equity Group | |
| Devin Sullivan | Conor Rodriguez |
| Managing Director | Associate |
| dsullivan@theequitygroup.com | crodriguez@theequitygroup.com |
